271 related articles for article (PubMed ID: 20650529)
1. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo.
Sanchez E; Shen J; Steinberg J; Li M; Wang C; Bonavida B; Chen H; Li ZW; Berenson JR
Leuk Res; 2011 Mar; 35(3):373-9. PubMed ID: 20650529
[TBL] [Abstract][Full Text] [Related]
2. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.
Maiso P; Carvajal-Vergara X; Ocio EM; López-Pérez R; Mateo G; Gutiérrez N; Atadja P; Pandiella A; San Miguel JF
Cancer Res; 2006 Jun; 66(11):5781-9. PubMed ID: 16740717
[TBL] [Abstract][Full Text] [Related]
3. Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.
Kaiser M; Lamottke B; Mieth M; Jensen MR; Quadt C; Garcia-Echeverria C; Atadja P; Heider U; von Metzler I; Türkmen S; Sezer O
Eur J Haematol; 2010 Apr; 84(4):337-44. PubMed ID: 20028416
[TBL] [Abstract][Full Text] [Related]
4. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR
Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977
[TBL] [Abstract][Full Text] [Related]
5. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells.
Mandl-Weber S; Meinel FG; Jankowsky R; Oduncu F; Schmidmaier R; Baumann P
Br J Haematol; 2010 May; 149(4):518-28. PubMed ID: 20201941
[TBL] [Abstract][Full Text] [Related]
6. The HDAC inhibitor LBH589 enhances the antimyeloma effects of the IGF-1RTK inhibitor picropodophyllin.
Lemaire M; Fristedt C; Agarwal P; Menu E; Van Valckenborgh E; De Bruyne E; Österborg A; Atadja P; Larsson O; Axelson M; Van Camp B; Jernberg-Wiklund H; Vanderkerken K
Clin Cancer Res; 2012 Apr; 18(8):2230-9. PubMed ID: 22392915
[TBL] [Abstract][Full Text] [Related]
7. The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells.
Baumann P; Junghanns C; Mandl-Weber S; Strobl S; Oduncu F; Schmidmaier R
Br J Haematol; 2012 Mar; 156(5):633-42. PubMed ID: 22211565
[TBL] [Abstract][Full Text] [Related]
8. Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation.
Yu C; Friday BB; Lai JP; McCollum A; Atadja P; Roberts LR; Adjei AA
Clin Cancer Res; 2007 Feb; 13(4):1140-8. PubMed ID: 17317822
[TBL] [Abstract][Full Text] [Related]
9. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia.
Vilas-Zornoza A; Agirre X; Abizanda G; Moreno C; Segura V; De Martino Rodriguez A; José-Eneriz ES; Miranda E; Martín-Subero JI; Garate L; Blanco-Prieto MJ; García de Jalón JA; Rio P; Rifón J; Cigudosa JC; Martinez-Climent JA; Román-Gómez J; Calasanz MJ; Ribera JM; Prósper F
Leukemia; 2012 Jul; 26(7):1517-26. PubMed ID: 22307227
[TBL] [Abstract][Full Text] [Related]
10. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
[TBL] [Abstract][Full Text] [Related]
11. Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid.
Campbell RA; Sanchez E; Steinberg JA; Baritaki S; Gordon M; Wang C; Shalitin D; Chen H; Pang S; Bonavida B; Said J; Berenson JR
Br J Haematol; 2007 Aug; 138(4):467-78. PubMed ID: 17587338
[TBL] [Abstract][Full Text] [Related]
12. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges.
Atadja P
Cancer Lett; 2009 Aug; 280(2):233-41. PubMed ID: 19344997
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells.
Bai LY; Omar HA; Chiu CF; Chi ZP; Hu JL; Weng JR
Cancer Chemother Pharmacol; 2011 Aug; 68(2):489-96. PubMed ID: 21072520
[TBL] [Abstract][Full Text] [Related]
14. Pan-histone deacetylase inhibitor panobinostat sensitizes gastric cancer cells to anthracyclines via induction of CITED2.
Regel I; Merkl L; Friedrich T; Burgermeister E; Zimmermann W; Einwächter H; Herrmann K; Langer R; Röcken C; Hofheinz R; Schmid R; Ebert MP
Gastroenterology; 2012 Jul; 143(1):99-109.e10. PubMed ID: 22465428
[TBL] [Abstract][Full Text] [Related]
15. [Study on histone deacetylase inhibitor LBH589 induces apoptosis of multiple myeloma cells and its reversal of drug resistance mechanism].
Zhang L; Ma YP; Jia G
Zhonghua Xue Ye Xue Za Zhi; 2012 Nov; 33(11):926-31. PubMed ID: 23363750
[TBL] [Abstract][Full Text] [Related]
16. Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms.
Ma Y; Liu W; Zhang L; Jia G
Med Sci Monit; 2017 Oct; 23():5150-5157. PubMed ID: 29080899
[TBL] [Abstract][Full Text] [Related]
17. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
18. Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMullan C; Miller JW; Marks PA; Mitsiades N
Invest Ophthalmol Vis Sci; 2009 Sep; 50(9):4072-9. PubMed ID: 19387079
[TBL] [Abstract][Full Text] [Related]
19. Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo.
Park KC; Kim SW; Park JH; Song EH; Yang JW; Chung HJ; Jung HJ; Suh JS; Kwon HJ; Choi SH
Cancer Sci; 2011 Feb; 102(2):343-50. PubMed ID: 21159061
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells.
Sung ES; Kim A; Park JS; Chung J; Kwon MH; Kim YS
Apoptosis; 2010 Oct; 15(10):1256-69. PubMed ID: 20582477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]